Consolidated Statement Of Comprehensive Income

ONO PHARMACEUTICAL CO., LTD. - Filing #7242262

Concept 2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
Consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
50,047,000,000 JPY
50,047,000,000 JPY
119,000,000 JPY
50,166,000,000 JPY
127,977,000,000 JPY
127,977,000,000 JPY
128,040,000,000 JPY
62,000,000 JPY
Other comprehensive income
Items that will not be reclassified to profit or loss
Remeasurements of defined benefit plans
259,000,000 JPY
23,000,000 JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income
-6,517,000,000 JPY
8,109,000,000 JPY
Total of items that will not be reclassified to profit or loss
-6,259,000,000 JPY
8,128,000,000 JPY
Items that may be reclassified to profit or loss
Exchange differences on translation of foreign operations
-17,128,000,000 JPY
2,124,000,000 JPY
Effective portion of cash flow hedges
2,066,000,000 JPY
-402,000,000 JPY
Total of items that may be reclassified to profit or loss
-15,001,000,000 JPY
1,722,000,000 JPY
Other comprehensive income
-21,261,000,000 JPY
-21,261,000,000 JPY
0 JPY
-21,260,000,000 JPY
9,825,000,000 JPY
9,850,000,000 JPY
9,825,000,000 JPY
25,000,000 JPY
Comprehensive income
-21,261,000,000 JPY
28,786,000,000 JPY
50,047,000,000 JPY
JPY
JPY
119,000,000 JPY
28,905,000,000 JPY
JPY
137,803,000,000 JPY
127,977,000,000 JPY
137,890,000,000 JPY
JPY
9,825,000,000 JPY
87,000,000 JPY
JPY
JPY
Comprehensive income attributable to
Owners of parent
28,786,000,000 JPY
137,803,000,000 JPY
Non-controlling interests
119,000,000 JPY
87,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.